Effect of Platelet Injection on Burn Scar

Comparing the Effect of Platelet Rich Fibrin Injection with Microneedling Versus Normal Saline Injection with Microneedling in the Treatment of Atrophic Burn Scars: A Randomized Clinical Trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231209060308N1

Enrollment

Registered

2024-01-12

Start date

2024-02-20

Completion date

Unknown

Last updated

2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burn scar. Scar conditions and fibrosis of skin

Interventions

Intervention 1: Control group: Receiving microneedling along with injection of normal saline. Intervention 2: Intervention group: Receiving microneedling along with injection of platelet-rich fibrin i

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Presence of at least two atrophic burn scars anywhere on the body in a symmetrical pattern. Age between 18-60 years. Both male and female genders are included in this study.

Exclusion criteria

Exclusion criteria: Patients with underlying conditions such as diabetes, blood clotting disorders, and immunodeficiency disorders. Pregnant patients or those planning to become pregnant. Patients diagnosed with any malignancy. Smokers with more than one pack of cigarettes per day (Heavy Smokers) Patients who have received another treatment for their scars within the 3-month period prior to the commencement of the intervention, which may have led to collagen stimulation. Patients who do not have the mental capacity to provide consent for participation in the study or to respond to researchers' inquiries.

Design outcomes

Primary

Measure	Time frame
Patient and Observer Scar Assessment Scale (POSAS) points. Timepoint: In the first visit, the initial treatment session, one month, and three months after the last treatment session. Method of measurement: Patient and Observer Scar Assessment Scale (POSAS).;Changes in skin tone evenness. Timepoint: In the initial treatment session, one month, and three months after the last treatment session. Method of measurement: VisioFace.;Local inflammatory or irritating adverse events. Timepoint: Within two weeks after each treatment session. Method of measurement: Patient visit or report.;Hemosiderin staining. Timepoint: Within two weeks after each treatment session. Method of measurement: Patient visit or report.;Herpes. Timepoint: Within two weeks after each treatment session. Method of measurement: Patient visit or report.;Hypersensitivity reactions. Timepoint: Within two weeks after each treatment session. Method of measurement: Patient visit or report.	—

Measure

Time frame

Patient and Observer Scar Assessment Scale (POSAS) points. Timepoint: In the first visit, the initial treatment session, one month, and three months after the last treatment session. Method of measurement: Patient and Observer Scar Assessment Scale (POSAS).;Changes in skin tone evenness. Timepoint: In the initial treatment session, one month, and three months after the last treatment session. Method of measurement: VisioFace.;Local inflammatory or irritating adverse events. Timepoint: Within two weeks after each treatment session. Method of measurement: Patient visit or report.;Hemosiderin staining. Timepoint: Within two weeks after each treatment session. Method of measurement: Patient visit or report.;Herpes. Timepoint: Within two weeks after each treatment session. Method of measurement: Patient visit or report.;Hypersensitivity reactions. Timepoint: Within two weeks after each treatment session. Method of measurement: Patient visit or report.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzan Moodi

Iran University of Medical Sciences

dr.farzanmoodi@gmail.com+98 21 8601 7501

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026